EUCTR2008-005560-13-DE进行中（未招募）1 期
A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II) - HIDIT-II
Medizinische Hochschule Hannover0 个研究点目标入组 70 人开始时间: 2009年6月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age >= 18 years;
- •2. Positive HBsAg, for at least the prior 6 months, positive anti-HDV for at least 3 months and positive for HDV-RNA by PCR within the screening period.
- •3. Elevated serum ALT >= ULN but <= 10X ULN as determined by two abnormal values taken > 1 month apart during the 12 months before the first dose of study drug with at least one of the determinations obtained <=35 days prior to the first dose.
- •4. A liver biopsy obtained within the past 12 months demonstrating liver disease consistent with chronic hepatitis. Patients with cirrhosis (e.g. Metavir F4, Ishak fibrosis score = 5-6) on liver biopsy must also have a liver imaging investigation to rule out hepatic carcinoma.
- •5. Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24 hour period prior to the first dose of test drug. Additionally, all fertile males with partners of childbearing age and females should use two reliable forms of effective contraception (combined) throughout the entire period of the study (treatment and for 4 months after treatment completion ): these may include, but are not limited to, birth control pills, IUDs, condoms, diaphragms, implants, surgical sterilization, or being in a post-menopausal state
- •6.Creatinine clearance > = 70 mL/min by the following formula:
- •((140-age in years) (body weight (kg)):((72) (serum creatinine [mg/dl]))
- •[Note: multiply estimated rate by 0.85 for women]
- •7. written informent consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients must not have received antiviral therapy for their chronic hepatitis D within the previous 6 months. Patients who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation in the study are also excluded. Exception: patients who have had a limited (<=7 day) course of acyclovir for herpetic lesions more than 1 month prior to the first administration of test drug are not excluded.
- •2. Positive test at screening for HAV-Ag IgM, HCV-RNA or HCV-Ag or HIV-Ag.
- •3.Serum concentrations of ceruloplasmin or alfa1-antitrypsin consistent with an increased risk of metabolic liver disease.
- •4. Evidence of decompensated liver disease (Childs B-C).
- •5. History or other evidence of a medical condition associated with chronic liver disease (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures, thalassemia).
- •6. Women with ongoing pregnancy or who are breast feeding.
- •7. WBC count of <3.000 cells/ mm3; neutrophil count <1.500 cells/mm3or platelet count <90.000 cells/mm3.
- •8. Evidence of alcohol and/or drug abuse within one year of entry.
- •9. Patients are excluded if any history of psychiatric disease, especially depression, or of suicidal attempts is evident.
- •10. History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis).
- •11. History or other evidence of decompensated liver disease.
- •(Coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypo-albuminemia, ascites, and bleeding from oesophageal varices are conditions consistent with decompensated liver disease)
- •12. History or other evidence of chronic pulmonary disease associated with functional limitation.
- •13. History of severe cardiac disease (e.g., NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases).
- •14. Evidence of an active or suspected cancer or a history of malignancy where there is a risk of cancer to reccur.
- •15.History of having received any systemic anti-neoplastic (including radiation) or immunomodulatory treatment (including systemic corticosteroids) <= 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.
- •16. History of any organ transplantation with an existing functional graft
- •17. History of thyroid disease poorly controlled on prescribed medications. Patients with elevated thyroid stimulating hormone concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded.
- •18. History or evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration) or clinically relevant ophthalmological disorder (e.g. due to diabetes mellitus or hypertension)
- •19. Inability or unwillingness to provide informed consent or abide by the requirements of the study.
- •20. History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
- •21. Patients with a value of alpha-fetoprotein >100 ng/mL are excluded, unless stability (less than 10% increase) has been documented over at least the previous 3 months.
- •22. Reassessments: If a patient fails to meet the above inclusion /e
研究者
相似试验
进行中（未招募）
1 期
A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II) - HIDIT-IITo compare the virological efficacy (HDV-RNA) and safety of 96 weeks of therapy with pegylated interferon-alfa-2a plus tenovofir to 96 weeks of therapy with pegylated interferon-alfa-2a plus placebo for the treatment with chronic delta hepatits virus.MedDRA version: 9.1Level: LLTClassification code 10047455Term: Viral hepatitis B without mention of hepatic coma, with hepatitis deltaEUCTR2008-005560-13-GRMedizinische Hochschule Hannover70
已完成
不适用
A multicenter randomised study comparing the efficacy of adefovir dipivoxil versus pegylated interferon alpha-2a plus placebo versus adefovir dipivoxil plus peglyated interferon alpha-2a for the treatment of chronic delta hepatitisAdults with chronic delta hepatitisInfections and InfestationsISRCTN83587695Hannover Medical School (MHH) (Germany)69
进行中（未招募）
不适用
A multicentre randomised trial comparing the effects of 2% chlorhexidine gluconate in 70% isopropyl alcohol as a skin, exit site and catheter hub cleansing agent versus other forms of chlorhexidine gluconate which are in routine use, on central venous catheter-related infections in haemodialysis patientsPrevention of central venous catheter-related infections in haemodialysis patients.This trial will evaluate the effectiveness of 2% chlorhexidine gluconate in 70%isopropyl alcohol as a skin, exit site and catheter hub cleansing agent in the reduction of CVC-related infections in haemodialysis patients, in comparison to the other forms of chlorhexidine gluconate that are in routine use in dialysis centres in Ireland.EUCTR2010-019984-12-IEAdelaide & Meath Hospital, incorporating The National Children's Hospital180
招募中
不适用
A Randomized Multicenter Study Comparing the Effectiveness of Hemi- Versus Total Shoulder Arthroplasty in Patients With a Degenerative Joint DiseaseM19.91M15M15-M19PolyarthrosisArthrosisDRKS00003072AO Foundation94
已完成
不适用
Efficacy of transfusions with platelets stored in platelet additive solution II versus plasmaPlatelet transfusionSigns and SymptomsTransfusionISRCTN52543592eyenburg Hospital (The Netherlands) - Department of Hematology195